source
- Wave Life Sciences reports stronger weight-loss effect of WVE-007 in patients with higher BMI and excess body fatWave Life Sciences presented data at ObesityWeek 2026 from its mid-stage INLIGHT trial of the investigational siRNA drug WVE-007. The analysis of three cohorts showed that participants with higher…
- CG Oncology's oncolytic therapy shows positive Phase 3 results in non-muscle invasive bladder cancerCG Oncology announced that its oncolytic immunotherapy, cretostimogene grenadenorepvec, achieved its primary endpoints in a Phase 3 trial involving patients with non-muscle invasive bladder cancer.…Endpoints · 1d agoPositive readoutPositive